5 Top Growth Stocks Down Over 20% in 2024: Buy Opportunitiesby Terry Bingman 25.04.2024Adobe, Albemarle, Intel, and Lululemon stocks have experienced mixed outcomes in 2024 after their impressive gains in 2023. The Motley ...
$38.4B Deposit Flight Hits Wells Fargo and Citigroup, JPMorgan CEO Warns Fedby Mark Eisenberg 25.04.2024Two major US banks are experiencing billions of dollars in deposit outflows, while other regional banks do not face the ...
Automate Vacuuming & Mopping: $400 Off Roomba Combo J9+by Lilu Anderson 25.04.2024iRobot's Roomba Combo J9+ is on sale for $999, $400 off its usual price. It features a motor that lifts ...
Enbridge: Top High-Yield Dividend Stockby Mark Eisenberg 25.04.2024Enbridge aims to pay out 60-70% of its cash flow in dividends while retaining the rest for new investments. A ...
A16z Promotes Jennifer Li to Help Lead New $1.25B Infrastructure Fundby Mark Eisenberg 25.04.2024Silicon Valley venture capital giant a16z raised $7.2 billion, with the infrastructure fund being a part of it. It has ...
Grayscale’s Mini Bitcoin ETF to Offer Lowest 0.15% Feeby John Darbie 25.04.2024Grayscale will introduce the Bitcoin Mini Trust, contributing 10% of GBTC assets to the new trust. Shares will be distributed ...
Air Force Achieves Historic AI Dogfight Successby Lilu Anderson 25.04.2024The Air Force conducted AI dogfights at Edwards Air Force Base in California, breaking barriers in combat aviation. The results ...
Fed District Surveys Uncover Signs of Economic Strainby Terry Bingman 25.04.2024The surge in insurance prices raises concerns over interest rates as the central bank’s efforts to achieve price stability may ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment?by Mark Eisenberg 25.04.2024Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
IMF’s Gopinath Warns of Rising U.S. Deficitsby Terry Bingman 25.04.2024Gopinath warns that US deficits will continue to rise, contributing to global growth, while emphasizing the need for policy prescriptions.